Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Therapy
Interventions
DRUG

Cilostazol, Probucol / placebo of probucol

An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.

Trial Locations (1)

Unknown

Severance Hospital, Yonsei University Health System, Seoul

Sponsors
All Listed Sponsors
collaborator

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Yonsei University

OTHER